Helus Pharma appointed Dr. Ken Kramer as Senior Vice President of Medical Affairs, effective immediately. Kramer brings more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, evidence generation, and engagement with key opinion leaders.
Most recently, Kramer served as Vice President and Head of Medical Neuroscience at Bristol Myers Squibb, where he led an integrated medical strategy team that successfully launched the first new schizophrenia treatment in over seven decades. At Karuna Therapeutics, where he served as Vice President and Head of Medical Affairs, Kramer built and expanded medical capabilities during significant organizational growth and supported the organization through its acquisition. Earlier in his career, he spent more than a decade leading U.S. psychiatry medical affairs teams at AbbVie and its predecessor organizations, contributing to multiple successful product launches.
Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for adjunctive treatment of major depressive disorder, which received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Ireland.
Kramer holds a Ph.D. in Neuropharmacology from New York University and an M.S. in Neuroscience and B.S. in Biology from the University of Rochester. The company cited his appointment as critical to strengthening scientific and clinical engagement as Helus advances its pipeline.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/helus-pharma-strengthens-medical-leadership-by-appointing-dr-ken-kramer-as-senior-vice-president-medical-affairs